GlassScriptPhysician profile
Robert J Brauer
NPI 1063401412
$7,452.83
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.95 · 2020: $641 · 2021: $2,318 · 2022: $1,566 · 2023: $928 · 2024: $1,461 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.13 |
| Education | $272.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,754.99 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $1,078.94 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $560.07 | 2020-2024 | Invega Trinza, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $521.91 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $485.37 | 2020-2025 | Caplyta |
| Validus Pharmaceuticals LLC | $469.67 | 2020-2021 | |
| Lundbeck LLC | $382.68 | 2020-2023 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $369.65 | 2020-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $349.04 | 2019-2022 | |
| Alkermes, INC. | $308.85 | 2020-2025 | Aristada, Vivitrol, Lybalvi |
| Supernus Pharmaceuticals, INC. | $277.15 | 2022-2024 | Qelbree |
| Allergan, INC. | $221.28 | 2020 | |
| Indivior INC. | $169.99 | 2021-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $117.81 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $105.80 | 2023-2025 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $83.65 | 2022-2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $79.39 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $29.79 | 2021-2022 | |
| Livanova USA, INC. | $27.34 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $17.65 | 2021 | |
| Neuronetics, INC. | $14.66 | 2020 | |
| Orexo US, INC. | $11.65 | 2021 | |
| Hikma Pharmaceuticals USA | $11.36 | 2021 | |
| Corium, LLC | $4.14 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.